Human Reproduction, Vol. 4, No. 6, pp. 667-669, 1989
© 1989 European Society of Human Reproduction and Embryology
other |
The value of GnRH analogue therapy in IVF in women with unexplained infertility
Sherman Fertility Institute, Golda Meir Medical Centre (Hasharon Hospital), Petah Tikva 49372 and Tel-Aviv University Medical School Israel
Correspondence: To whom correspondence should be addressed at Golda Meir Medical Centre
Seventy-six women with unexplained infertility, undergoing in-vitro fertilization and embryo transfer (IVF-embryo transfer), were selected for three different ovulation induction protocols. In group I, induction of ovulation was performed with pure follicle-stimulating hormone/human menopausal gonadotrophin/human chorionic gonadotrophin (pFSH/ HMG/HCG). Group II patients were given a combined therapy consisting of a gonadotrophin-releasing hormone (GnRH) analogue, decapeptyl (DTRP6) followed by pFSH/ HMG/HCG. In group III, patients underwent two IVF-embryo transfer cycles, serving as their own controls. The initial cycle was induced with pFSH/HMG/HCG while the second was stimulated using decapeptyl/pFSH/HMG/HCG. Significantly higher rates of fertilization, cleavage and pregnancy (P < 0.001, P < 0.07, P < 0.001, respectively) were achieved in group II patients to whom combined GnRH agonists and gonadotrophins were given. Furthermore, among group III patients, no pregnancies occurred during the initial IVF-embryo transfer cycles whereas a 23% pregnancy rate (P < 0.001) was obtained after GnRH agonist therapy. Our results indicate that the combination of GnRH agonists and gonadotrophins is of value in cases of unexplained infertility. Further, larger studies must be performed before the true efficacy of this mode of therapy can be determined in women with unexplained infertility.
Key words: GnRH/GnRH analogue/IVF/embryo transfer/nexplained infertility